The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy
Open accessAbstract
Chemotherapeutic drugs chronically administered to tumor-bearing mice, using a frequent schedule at doses substantially lower than the maximum tolerated dose (MTD) (i.e., metronomic dosing), can cause sustained and potent antiangiogenic effects by targeting the endothelial cells of newly growing tumor blood vessels. These effects appear to occur in the absence of an increase in the severity of side effects caused by destruction of other cell types normally sensitive to MTD chemotherapy, suggesting a marked and selective sensitivity of activated endothelial cells, the basis of which is unknown. Here we report that protracted exposure of endothelial cells in vitro to low concentrations of several different anticancer agents, including microtubule inhibitors and an alkylating agent, caused marked induction of gene and protein expression of TSP-1, a potent and endothelial-specific inhibitor of angiogenesis. Increases in circulating TSP-1 were also detected in the plasma of human tumor-bearing severe combined immunodeficient mice treated with metronomic low-dose cyclophosphamide. Most importantly, the antiangiogenic and antitumor effects of low-dose continuous cyclophosphamide were lost in TSP-1-null C57BL/6 mice, whereas, in contrast, these effects were retained by using a MTD schedule of the same drug. Taken together, the results implicate TSP-1 as a secondary mediator of the antiangiogenic effects of at least some low-dose metronomic chemotherapy regimens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Watnick, R. S., Cheng, Y.-N., Rangarajan, A., Ince, T. A., & Weinberg, R. A. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00030-8 · Cited by 318
RetractedLyden, D., Hattori, K., Dias, S., Costa, C., Blaikie, P., Butros, L., Chadburn, A., Heissig, B., Marks, W., Witte, L., et al. (2001) · Nature Medicine · doi:10.1038/nm1101-1194 · Cited by 1,860
Browder, T. D., Butterfield, C., Kräling, B. M., Shi, B., Marshall, B., OʼReilly, M., & Folkman, J. (2000) · PubMed · Cited by 1,543
Control of Angiogenesis in Fibroblasts by p53 Regulation of Thrombospondin-1
Dameron, K. M., Volpert, O. V., Tainsky, M. A., & Bouck, N. (1994) · Science · doi:10.1126/science.7521539 · Cited by 1,438
Klement, G., Baruchel, S., Rak, J., Man, S., Clark, K., Hicklin, D. J., Bohlen, P., & Kerbel, R. S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8829 · Cited by 1,168
Self-citationInterferon Alfa-2a Therapy for Life-Threatening Hemangiomas of Infancy
Ezekowitz, R. A. B., Mulliken, J. B., & Folkman, J. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205283262203 · Cited by 1,071
Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1
Jiménez, B., Volpert, O. V., Crawford, S. E., Febbraio, M., Silverstein, R. L., & Bouck, N. (2000) · Nature Medicine · doi:10.1038/71517 · Cited by 1,020
Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice
Hanahan, D., Bergers, G., & Bergsland, E. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9872 · Cited by 865
Eberhard, A., Kahlert, S., Goede, V., Hemmerlein, B., Plate, K. H., & Augustin, H. G. (2000) · PubMed · Cited by 753
CD36 Mediates the In Vitro Inhibitory Effects of Thrombospondin-1 on Endothelial Cells
Dawson, D. W., Pearce, S. F. A., Zhong, R., Silverstein, R. L., Frazier, W. A., & Bouck, N. P. (1997) · The Journal of Cell Biology · doi:10.1083/jcb.138.3.707 · Cited by 676
Cited by
Normalization of the Vasculature for Treatment of Cancer and Other Diseases
Goel, S., Duda, D. G., Xu, L., Munn, L. L., Boucher, Y., Fukumura, D., & Jain, R. K. (2011) · Physiological Reviews · doi:10.1152/physrev.00038.2010 · Cited by 1,605
Folkman, J. (2006) · Annual Review of Medicine · doi:10.1146/annurev.med.57.121304.131306 · Cited by 1,209
Angiogenic and cell survival functions of Vascular Endothelial Growth Factor (VEGF)
Byrne, A. M., Bouchier-Hayes, D. J., & Harmey, J. H. (2005) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2005.tb00379.x · Cited by 744
Molecular Basis for the Regulation of Angiogenesis by Thrombospondin-1 and -2
Lawler, P. R., & Lawler, J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006627 · Cited by 532
Self-citationNormalizing Function of Tumor Vessels: Progress, Opportunities, and Challenges
Martin, J. D., Seano, G., & Jain, R. K. (2019) · Annual Review of Physiology · doi:10.1146/annurev-physiol-020518-114700 · Cited by 530
Metadata
- Authors
- Bocci, G., Francia, G., Man, S., Lawler, J., & Kerbel, R. S.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2003-10-15
- Volume
- 100
- Issue
- 22
- Pages
- 12917-12922
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2102392974
- Cited by
- 414
- References
- 35
- FWCI
- 7.83
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. https://app.cochat.ai/papers/10.1073/pnas.2135406100
- The paper
- Bocci, G., Francia, G., Man, S., Lawler, J., & Kerbel, R. S. (2003). Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2135406100
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
